C-PDS4BioXtek
placental tissues, regenerative therapeutics, biologics
repairingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PDS4
C-PDS4C-PDS4placental tissues, regenerative therapeutics, biologics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Evaluation of Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing
The clinical investigation is a non-randomized, multicenter, open-label, prospective, exposure-time escalation clinical investigation. The clinical investigation is designed to assess the clinical safety and performance of the Oncomagnetic Device.
The goal of this clinical research study is to learn about a new minimally invasive glucose monitoring device called Fluorescence Affinity Sensor (FAS). In this study, the FAS will be used to determine its effectiveness for glucose monitoring. Researchers want to find out how the device performs at two different body sites (forearm and abdomen) over 4 hours. The safety and comfort level of the device will also be studied.
This proposal is designed as a pilot study for the use of laser ablation for local control of symptomatic (e.g compressive) benign thyroid masses in 20 patients.
The purpose of this study is to determine if the stereotactic, MR guided, laser interstitial thermal therapy treatment technique can be safety and efficiently used for human brain metastasis and primary brain tumors.
The purpose of this study is to determine if the, MR guided, laser interstitial thermal therapy (LITT) treatment technique can be safety and efficiently used for the human liver metastasis
BioTex - Biohybrid & Medical Textiles | Institute of Applied Medical Engineering | RWTH Aachen University | EN Skip to Content Skip to Main Navigation Skip to Quick Access Skip to Search Skip to Footer Tools RWTHonline RWTHcontacts RWTHmoodle Intranet Services Dining Hall Menus RWTH Navigator Student Resources and Support Official Announcements Institutions University Library IT Center Center for Teaching and Learning Services Athletics and Recreation Central University Administration Search by Name RWTH Home Quick Access DE Institute of Applied Medical Engineering Academics Research The I
This is a really important milestone... - NurExone Biologic Facebook Log In NurExone Biologic's Post NurExone Biologic April 7 · Shared with Public This is a really important milestone for NurExone.... Today’s strategic (non-binding) LOI between our U.S. subsidiary, Exo-Top, and BioXtek marks an important step on two critical fronts: therapeutic advancement and commercial readiness. On the therapeutic side, the planned collaboration is expected to support U.S. GMP manufacturing and clinical supply of naïve MSC exosomes, an important building block for the future clinical development of Ex
NurExone Biologic’s U.S. Subsidiary Exo-Top and --> Accessibility: Skip TopNav NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization April 07, 2026 09:18 ET | Source: NurExone Biologic Inc NurExone Biologic Inc TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) and BioXtek Inc. (“ BioXtek ”) today announced that Exo-Top Inc., NurExone’s wholly owned U.S. subsidiary, … etics Exosome Products Market Size, Share & Trends Analysis Distribution by Application, By Biological Source, By Product Format, End User, and Segment Forecasts, 2025-2034 ” Tags Strategic Partnership Exosome Production Exosomes Exo-Top US markets Regenerative Medicine GMP-grade Strategic Collaborations GlobeNewswire Recommended Reading June 24, 2026 17:01 ET | Source: NurExone Biologic Inc Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Na&
Biotex Inc --> Menu Toggle Company About Us Our Process Leadership Facility Careers Expertise Industrial Design Mechanical Electrical Software Services Research & Strategy Product Development Criterion Who We Are Consulting & Testing Services Contact Us Manufacturing Clinical What is a CRO Who We Are Consulting & Services Start-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog Contact
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization - Exosome RNA --> Don't Miss ’Footprint of Death’ gives new clues to cell life Positive CAR-exosome in vitro tumour killing demonstrated in ovarian cancer cells UC San Diego Researchers Receive ARPA-H Award to Make Birth Safer iMSC-derived extracellular vesicles may offer a new approach for osteoarthritis treatment Maternal weight may influence microbiota signalling in amniotic fluid SECmeres outperform extracellular vesicles as potential blood RNA biomarkers … etics Exosome Products Market Size, Share & Trends Analysis Distribution by Application, By Biological Source, By Product Format, End User, and Segment Forecasts, 2025-2034” Source – NurExone Biologic BioXtek Inc. Drug delivery Exo-Top Inc. exosome commercialization Exosomes extracellular vesicles GMP manufacturing MSC exosomes NurExone Biologic Inc. regenerative medicine stem cell therapy 2026-04-20 Exosome RNA Administrator tweet Tagged with: BioXtek Inc. Drug del … ated in ovarian cancer cells 3 days ago UC San Diego Researchers Receive ARPA-H Award to Make Birth Safer 4 days ago iMSC-derived extracellular vesicles may offer a new approach for osteoarthritis treatment 4 days ago Maternal weight may influence microbiota signalling in amniotic fluid 5 days ago SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer’s disease 5 days ago Social Networking Pages Exosome RNA 3,188 Followers 123 Fans © Copyri
NurExone Biologic Signs LOI with BioXtek for Exosome Production Partnership | Lior Shaltiel, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … er” or “itch signaling.” Interested? Read more here: https://hubs.li/Q049fYWx0 #RFP #Innovation #OpenInnovation #Technology #NineSigma …more 9 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 4,552 followers 382 Posts 5 Articles View Profile Connect More from this author The big open day event of the BioMed-MBA program! Lior Shaltiel, PhD 9y The BioMed-MBA introduction meeting Lior Shaltiel, PhD 9y The new MBA program in Biomedical management at t
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Products & Pipeline - Bioxtek Skip to content Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Contact BioXtek Therapeutic Portfolio Precision-engineered biologics From advanced extracellular matrices to pipeline biologic injectables, our configurations are precision-engineered for diverse clinical applications. Flagship · FDA 1271/36 Sanoplast® DHAAM Dehydrated and/or L … tions for biologic license in process. This is not an FDA approved product. FDA application in process. Available in Cryopreserved (-80C) and Lyophilized (ambient temperature) versions. ~150 Billion exosomes per 1/mL. Rich in growth factors, microRNA, peptides, and messengerRNA components. Derived from Wharton's jelly and Amniotic Fluid. Processed under the tightest quality standards, with the highest PURITY and QUALITY. Cosmetic Series BioXjel+ Cosmetic Applications A topica … 10 Million and 25 Million cell vials. This is not an FDA approved product. FDA application in process. MSCs derived from Wharton's jelly. 3D cultured in a stressed hypoxic environment. Guaranteed 90% viability. Full Certificate of Analysis (COA) with each vial. Sanoplast® — Full Product Numbers & Sizing Matrix View Size Matrix SIZE (CM) AREA (CM²) SINGLE (SCM) DUAL AA (SAA) DUAL AC (SAC) TRI (STR) QUAD (SQD) 2×2 4 SCM-0202 SAA-0202 SAC-0202 STR-0202 SQD-0202 2×
Products & Pipeline - Bioxtek Skip to content Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Contact BioXtek Therapeutic Portfolio Precision-engineered biologics From advanced extracellular matrices to pipeline biologic injectables, our configurations are precision-engineered for diverse clinical applications. Flagship · FDA 1271/36 Sanoplast® DHAAM Dehydrated and/or L … tions for biologic license in process. This is not an FDA approved product. FDA application in process. Available in Cryopreserved (-80C) and Lyophilized (ambient temperature) versions. ~150 Billion exosomes per 1/mL. Rich in growth factors, microRNA, peptides, and messengerRNA components. Derived from Wharton's jelly and Amniotic Fluid. Processed under the tightest quality standards, with the highest PURITY and QUALITY. Cosmetic Series BioXjel+ Cosmetic Applications A topica … 10 Million and 25 Million cell vials. This is not an FDA approved product. FDA application in process. MSCs derived from Wharton's jelly. 3D cultured in a stressed hypoxic environment. Guaranteed 90% viability. Full Certificate of Analysis (COA) with each vial. Sanoplast® — Full Product Numbers & Sizing Matrix View Size Matrix SIZE (CM) AREA (CM²) SINGLE (SCM) DUAL AA (SAA) DUAL AC (SAC) TRI (STR) QUAD (SQD) 2×2 4 SCM-0202 SAA-0202 SAC-0202 STR-0202 SQD-0202 2×
Ictero Medical Closes $6M Series A Financing - MedTech Innovator Open Menu Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager Operations, Finance & Contracts Coordinator MedTech Innovator Fellows Program Join the Ecosystem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Heart & Brain Health Accelerator Track MedTech Innovator Plastic S … 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Company Videos Portfolio Companies MEMBER News Press Releases Cohort & Partner News Ecosystem Job Opportunities Log in Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager Operations, Fina … tem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Heart & Brain Health Accelerator Track MedTech Innovator Plastic Surgery Accelerator Track Webinars 2026 Cohort Companies Company Videos Alumni Portfolio Asia Pacific APAC Accelerator US Market Access Webinars 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Comp … well as capital support from MedTex Ventures through its Biotex Medical Device Fund. “We are excited about working with the Ictero team to advance its technology, which we believe can significantly improve patient experiences and outcomes by providing a non-surgical alternative to treating gallbladder disease,” says Biotex CEO, Ashok Gowda. “MedTex Ventures is enthusiastic about Ictero’s novel cryoablation technology and its potential to solve the unmet need of inoperable pa … ero Medical was founded in 2018 as part of the Texas Medical Center’s Biodesign Fellowship program and is developing the first cryoablation system to treat high-risk patients with gallstone disease. Ictero’s catheter-based technology can be used in the interventional radiology suite to treat the gallbladder without having to remove it, ultimately
Portfolio Companies Archive - InNegev Skip to content Our Story About Us Leadership Partners Media Programs Portfolio Ecosystem Blog Contact us Menu Our Story About Us Leadership Partners Media Programs Portfolio Ecosystem Blog Contact us Apply Archives: Portfolio Companies AquaGene MotionAnalytics Snow Polymer Lamin BioTex Texperience XtriON Qortein Nobify Fungit Emnotion Next → © 2024 All rights reserved to InNegev Linkedin-in Facebook-f Instagram Contact Us Terms & Conditions Privacy Policy Cookie Policy Accessibility Skip to content Open toolbar Accessibility Tools Accessibility Tools
%PDF-1.4 %���� %ABCpdf 13303 31 0 obj > endobj xref 31 19 0000000032 00000 n 0000001631 00000 n 0000001794 00000 n 0000001975 00000 n 0000002162 00000 n 0000002459 00000 n 0000002567 00000 n 0000002672 00000 n 0000002780 00000 n 0000002883 00000 n 0000003122 00000 n 0000018567 00000 n 0000018724 00000 n 0000018976 00000 n 0000019071 00000 n 0000023191 00000 n 0000025067 00000 n 0000040849 00000 n 0000046991 00000 n trailer ] /Prev 140889 /Root 32 0 R /Size 50 /Source (WeJXFxNO4fJduyUMetTcP9+oaONfINN4+d6z8u7DH0wP4nzAKHDVd8ttJEBfnWZfB9khgm8VtCFmyd8gIrwOjQRAIjPsWhM4vgMCV\ 8KvVF/K8lfG18Qbfr+gT3TpN
MedTex Ventures | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors MedTex Ventures MedTex Ventures Norwalk, Connecticut medtexventures.com Overview MedTex Ventures is a venture capital firm focused on early-stage medical devices. The team consists of expert investors with a diverse set of backgrounds representing the buy-side, sell-side, and medical device industry. They have partnered with Biotex Inc. to help source, analyze, develop, finance and manage medical device c
Bluejay Diagnostics And Argonaut Manufacturing Services Announce Strategic Partnership Get more pharma outsourcing insight with our FREE newsletter sign me up Log In or Subscribe Explore CDMO Outsourcing Outsourcing 101 Preparing to Outsource Selecting a CDMO Onboarding & Tech Transfer Managing CDMOs Find Suppliers Bioanalytical Services Biologic Drug Substance Biologic Drug Product Cell & Gene Clinical Supply Fill/Finish Small Molecule API Small Molecule Drug Product Watch Now STREAM Video Channel Outsourced Pharma Capabilities Update Outsourced Pharma Live The Outsourcing Advisor Eve … tcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis. About Bluejay Diagnostics: Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-
MedTex Ventures | Norwalk Venture Capital | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home Venture Capital MedTex Ventures Venture Capital ● RIA · CRD 313202 SEC-Registered Private Fund Adviser Updated: Jun 3, 2026 MedTex Ventures Venture capital firm focused on early stage medical devices | MedTex Ventures is a venture capital firm focused on early stage medical devices. MedTex Ventures Venture capital firm focused on early stage medical devices | MedTex Ventures is a venture capital firm focused on early stage medical devices. Our team consists of expert investo … h Entrepreneurs Management Next venture capital firm Medtronic Employee Pension Fund Need institutional-grade insight on venture capital firms ? Altss delivers: Principals with verified direct contacts Allocation history by asset class OSINT-derived deal signals Book a demo Prefer a guided tour? We’ll walk you through: Interactive funding timelines Custom mandate & allocation filters Book a demo Browse by category Venture capital firms Registered investment advisers More … Preqin Altss vs PitchBook Altss vs FINTRX Altss vs Dakota Company About us Why Submit Data How we Collect Data Press Careers Contribute Submit your firm Submit a deal Submit a fund
%PDF-1.6 %���� 61477 0 obj > endobj 61496 0 obj >/Filter/FlateDecode/ID[ ]/Index[61477 30]/Info 61476 0 R/Length 101/Prev 10080312/Root 61478 0 R/Size 61507/Type/XRef/W[1 3 1]>>stream h�bbd```b`�6� � ��/�d � `� LN���`� ��"���`RDrŀMK��� ҸH2������>l�a`$��� ��@�� J endstream endobj startxref 0 %%EOF 61506 0 obj >stream h��X PT���}�X���$�]]�ծ ��˂ ����HWc�����εY��A�Q AԵJ��� �����s֤M�؆qB�8i�sﲺ��:I���w���������sw�^ �o%(P ��ѥ�@� �(A ��aJڀ �H�H! X"`$�5V�U�����3/����˲ ������ lל����S\��9�� ��1�eKV&[����� s��2�#�O����&M8B{��_�òn[��P����,� i��Ppt�\#=�� �4 … ��EF��q�rf� CįQ9ZY�$r!���6m �)�4� ��V�9�k�J�$#�� Fь�X��٥�C��p�[��ģ)C���S�;rFP#�I�m�K�G ɺ��z���j>>��X�9,�ZL-j��Ib�k��ȉ8�˚?v�t���� �x������P�IO}�_ay@ ��:����|Ve�6�����ubd/e�3 T� Sؓ�7X����?MM�!���Լu�O��t����P Cbt;���i����ް��a��@gW��#�@��4c�9.D���o� z2>M�5��i�~�u0� �q�s �wQ�9�ǸLt��삟�Mz)>���kɝ���I�;���io�"���U)��]$Y���L >� $����$T����:gUo$���UK���,�C�`sCMAJMÄ��K��C(��g]���ٮ9�s�U�G�0?����L�5��� �QM%��0O�l��5&���`�Ƒ 1,��x�'���{��k+�mY�}��� … 70 adobe:docid:indd:b0f6ced5-b9fc-11e1-8a5f-8285fd44c8e9 default converted from application/x-indesign to application/pdf Adobe InDesign CS6 (Windows) / 2025-08-22T16:47:33+05:30 2025-08-22T16:47:33+05:30 2025-08-22T16:47:35+05:30 2025-08-22T16:47:35+05:30 Adobe InDesign CS6 (Windows) application/pdf Adobe PDF Library 10.0.1 False endstream endobj 7006 0 obj >stream uuid:540e75a6-e245-4288-a629-c676660717a6 adobe:docid:indd:b0f6ced5-b9fc-11e1-8a5f-8285fd44c8e9 xmp.id:6B081D16 … 2F adobe:docid:indd:b0f6ced5-b9fc-11e1-8a5f-8285fd44c8e9 default converted from application/x-indesign to application/pdf Adobe InDesign CS6 (Windows) / 2025-08-22T16:47:10+05:30 2025-08-22T16:47:10+05:30 2025-08-22T16:47:13+05:30 2025-08-22T16:47:13+05:30 Adobe InDesign CS6 (Windows) application/pdf Adobe PDF Library 10.0.1 False endstream endobj 7007 0 obj >stream uuid:ae08d6bf-6883-4d91-b1a2-9ae098a77533 adobe:docid:indd:b0f6ced5-b9fc-11e1-8a5f-8285fd44c8e9 xmp.id:278DF136 … 11 adobe:docid:indd:b0f6ced5-b9fc-11e1-8a5f-8285fd44c8e9 default converted from application/x-indesign to application/pdf Adobe InDesign CS6 (Windows) / 2025-08-23T12:33:26+05:30 2025-08-23T12:33:26+05:30 2025-08-23T12:33:30+05:30 2025-08-23T12:33:30+05:30 Adobe InDesign CS6 (Windows) application/pdf Adobe PDF Library 10.0.1 False endstream endob
ExoTop and BioXtek Collaborate on Exosome Manufacturing and Clinical Supply | NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & J … er” or “itch signaling.” Interested? Read more here: https://hubs.li/Q049fYWx0 #RFP #Innovation #OpenInnovation #Technology #NineSigma …more 9 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Los Angeles Biotech Networks 1,335 followers 2mo Report this post Okami Medical Announces First Patient Enrolled in ALPHA Registry https://lnkd.in/g5TFaVFe ALISO VIEJO, Calif., April 7, 2026 /PRNewswire/ — Okami Medical, a medical technology company pioneerin
BioXtek, LLC | Association for Advancing Tissue and Biologics Skip to main content Your Privacy Choices Notice at Collection × Top Bar Links News + Announcements About Us Current Members Careers Portal Login Search Accredited Establishment Search Toggle navigation Main navigation Why Tissue? Accreditation & Membership Prospective Members Institutional Accreditation Affiliate Membership Individual Membership Current Members Join a Council or Committee Member Resources Portal Login Standards & Regulatory AATB Bulletins Government Advocacy Correspondences Standards for Tissue
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
--> Auditing Services | Biotex Inc. Company About Us Our Process Leadership Facility Careers Expertise Industrial Design Mechanical Electrical Software Services Research & Strategy Product Development Criterion Who We Are Consulting & Testing Services Contact Us Manufacturing Clinical What is a CRO Who We Are Consulting & Services Start-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog … rt-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog Contact Us Company About Us Our Process Leadership Facility Careers Expertise Industrial Design Mechanical Electrical Software Services Research & Strategy Product Development Criterion Who We Are Consulting & Testing S … rt-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog Services Auditing services Ensuring Precision and Rigor in Trial Conclusion --> Our customized auditing services adhere to the highest standards to enhance the efficiency and quality of your clinical investigations. With our com … mprovement in your chosen QMS, CRO, and clinical investigation sites. REQUEST A PROPOSAL --> Start Your Journey Now Embark on the conclusive phase of your clinical trial with confidence, guided by our expertise and commitment to robust auditing services. Contact Our Team ----------------------> Previous - Clouse-out Services Next - Start-up Services About Us 114 Holmes Rd, Houston, TX 77045 +1 (713) 741-0111 [email protected] © 2026 Biotex Inc. Quick Links About Us Priva
Zeo ScientifiX 10-K details losses, going concern | ZEOX Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Sto … products will be treated by the FDA as biologics requiring a Biologics License Application and is preparing for potential limitations on U.S. revenues if adverse interpretations occur. Litigation and partnership execution risk: A planned joint venture with BioXtek did not close and is now the subject of court proceedings, and a terminated sales agreement with Exotropin has led to ongoing contractual disputes, adding legal cost and execution uncertainty. Insights Biotech equi … eding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  ☒   No ☐         Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accele … uture growth;   ● Expectations regarding available cash resources to fund current operations and future growth;   ● Our ability to comply with regulations governing the production and sale of our products;   ● Our ability to receive regulatory approvals;   ● Market opportunities for our services and products;   ● Clinical trial outcomes;   ● Our ability to compete effectively;   ● Our ability to resp … among other things, the Company having sufficient available working capital to fund the substantial costs of completing clinical trials, which the Company currently does not have, and ultimately, obtaining approval from the FDA.   Current FDA guidance requires that the sale of products that fall under Section 351 of the Public Health S
Our Approach - Bioxtek Skip to content Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Contact BioXtek Our Approach The BioPür Process® is our Platform Technology We create products from qualified ‘single birth’ placental donors. We create products across 3 categories: Membrane patches Injectable regenerative therapeutics Topical cosmetics Technology innovation BioXtek’s ma
false 2025 Q3 --10-31 0001557376 0001557376 2024-11-01 2025-07-31 0001557376 2025-09-12 0001557376 2025-07-31 0001557376 2024-10-31 0001557376 us-gaap:SeriesCPreferredStockMember 2025-07-31 0001557376 us-gaap:SeriesCPreferredStockMember 2024-10-31 0001557376 2025-05-01 2025-07-31 0001557376 2024-05-01 2024-07-31 0001557376 2023-11-01 2024-07-31 0001557376 us-gaap:CommonStockMember 2024-04-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001557376 us-gaap:RetainedEarningsMember 2024-04-30 0001557376 2024-04-30 0001557376 us-gaap:CommonStockMember 2025-04-30 0001557376 us-gaap:Add … eding 12 months (or for such shorter period that the Registrant was required to submit such files.) Yes  ☒   No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer,” “smaller reporting company” and & … ting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.   The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing m … #8220;HCT/Ps”) can only be sold pursuant to an approved biologics license application (“BLA”). The Company has not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products it currently produces would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s.   As a result of the above, the Company’s efforts to establish … will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing
BioXtek Employer Profile - ASABE Career Center Employers Home Products Post a Job My Account My Jobs My Clients Resume Bank My Candidates My Company My Templates Help Job Seekers Home My Account Job Search Products Career Planning Advice Insights Coaching Manage Resumes Job Alerts Company Directory Help Sign-in or Create Account Employer Job Seeker Post a Job We detected that Javascript is deactivated. Some functionality within the site may not work as expected. Career Center Home Company Directory Company Profile Company Profile BioXtek This company does not currently have a profile. Please r
Raven.config('https://[email protected]/147999').install(); InnovationMap X Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe INNOVATIONMAP EMAILS ARE AWESOME Sign up now About Us Advertise Submit a Story Terms of Use Privacy Policy Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe Houston medical device startup closes $6M series A money … received capital support from MedTex Ventures through its Biotex Medical Device Fund. “We are excited about working with the Ictero team to advance its technology, which we believe can significantly improve patient experiences and outcomes by providing a non-surgical alternative to treating gallbladder disease,” says Biotex CEO Ashok Gowda in the release. The fresh funds will be put toward further product development and initial clinical testing. “MedTex Ventures is enthusias … success.” Ictero was founded as a part of the Texas Medical Center’s Biodesign Fellowship program in 2018. Since launch, the company has received a Phase I NSF grant and closed a $1 million seed round co-led by the Texas Medical Center Venture Fund and Texas HALO Fund. “Ictero is at the forefront of pioneering cryotherapy for gallstone disease, and S3 Ventures is excited about the potential for Ictero’s novel solution to rapidly bring an impactful outcome to patients,” says … ew exits under its belt, and some of those entrepreneurs have stayed in town to fund future success stories. At Houston Exponential's second annual HX Capital Summit, four entrepreneurs discussed their exits, providing key lessons learned for entrepreneurs. Houston has some perks. One thing moderator Samantha Lewis, director at the GOOSE Society of Texas, asked each panelist was what made each entrepreneur start their companies in Houston — and furthermore, what made them … a group of angel investors that invest like a find would, but without having a fund. Between Kreuer and his team, they were involved in 10 startups before forming the investment group. "We could find developer and sales talent here, but to get to that higher executive talent, we had to go out to other places," Kreuer says. However, not
false 0001557376 0001557376 2024-11-01 2025-01-31 0001557376 dei:BusinessContactMember 2024-11-01 2025-01-31 0001557376 2024-10-31 0001557376 2023-10-31 0001557376 us-gaap:SeriesCPreferredStockMember 2024-10-31 0001557376 us-gaap:SeriesCPreferredStockMember 2023-10-31 0001557376 2025-01-31 0001557376 us-gaap:SeriesCPreferredStockMember 2025-01-31 0001557376 2023-11-01 2024-10-31 0001557376 2022-11-01 2023-10-31 0001557376 2023-11-01 2024-01-31 0001557376 us-gaap:CommonStockMember 2022-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2022-10-31 0001557376 us-gaap:RetainedEarningsMember 20 … rowth;     ● Expectations regarding available cash resources to fund current operations and future growth;     ● Our ability to comply with regulations governing the production and sale of our products;     ● Our ability to receive regulatory approvals;     ● Market opportunities for our services and products;     ● Clinical trial outcomes;     ● Our ability to compete effectively; … among other things, the Company having sufficient available working capital to fund the substantial costs of completing clinical trials, which the Company currently does not have, and ultimately, obtaining approval from the FDA.   Current FDA guidance requires that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue-based products (“ H … 220; HCT/Ps ”) can only be sold pursuant to an approved biologics license application (“ BLA ”).   We have not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products we currently produce would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s. However, we do not believe that our products fall within these guidelines … e also expect to experience negative cash flow for the foreseeable future as we fund our operating losses and capital expenditures. As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future. Our failure to achieve
%PDF-1.7 %���� 1 0 obj >/Metadata 1908 0 R/ViewerPreferences 1909 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��WYO#G~���PO��jiw��BZ�E��`#Eyp�a��M�����TO� >1�e آ��h�����C (N�J-Q�^���v��O�i x��:��C6��]��V�c �c�b� ��� �9P!.{� ��� ����}����LX���&��c����`�=����L� ��9Z���e9 .�����g�S~j� i:��1̭ �/7��硜��yx�� (�ׇ��vV֜�N��0��ɾ��8k��X�خ)��x����Nh,S��7�Ө��W$�Hu;a�����$��[�@R�V�SiYE(��m%�V��$�$�lY6uTN���4Z�����TV�_����� �`SL\I
Biotex and Dana Cup extend their... - Dana Cup Hjorring Facebook Log In Dana Cup Hjorring's Post Dana Cup Hjorring April 24, 2024 · Shared with Public Biotex and Dana Cup extend their collaboration Dana Cup is proud to announce that Biotex have extended their collaboration as a Dana Cup World Partner “Biotex share our passion towards young individuals and with their “Dirt is Good” philosophy the Dana Cup and Biotex is a match made in heaven. This summer, you will find Biotex in the heart of the Dana Cup Event Area, with a super fun activity says Thomas Gaardsøe, Partner & Event Manage … in forces once again with Dana Cup in celebrating the spirit of competition and fellowship This partnership is a perfect match, as both parties are united by a shared passion for empowering and fostering the development of young individuals At Biotex, we champion the notion that 'dirt is good' – it's an integral part of our journey towards self-improvement and living life to the fullest, just as every match at Dana Cup showcases the resilience and growth of you
ESVONC CONGRESS | ECT Workshop Sponsors Menu Home Discover our society Objectives Board Become a ESVONC member History Other Societies National Veterinary Oncology Societies Veterinary Oncology Societies in the world Internships Congress Venue City Accessibility Congress Venue Hotels Registration Vets Program Wednesday 20 May 2026 Thursday 21 May 2026 Friday 22 May 2026 Saturday 23 May 2026 Nurses Program Friday 22 May 2026 Saturday 23 May 2026 Nurse and Technician Presentations Social Program Sponsors and Exhibitors Sponsorship information Platinum Sponsors Silver Sponsors Bronze Sponsor ECT … How to get involved Clinical Research Ongoing Clinical trials Clinical Research Fund News Job offers Education Courses Clinical Trials Members Log-In Contact ECT Workshop Sponsors Hospitarea - BIOTEX Hospitarea is the official distributor of BIOTEX SRL, a medical technology company with more than 20 years in the medical device market. BIOTEX manufactures medical-grade devices, including electroporation systems for veterinary and human medicine, as well as de
BIOTEX INC. H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support BIOTEX INC. H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 2 Total Filings 2021-Present 100.0% Approval Rate Certified
Gerard L. Coté – PORTENT Skip to main content Search: Submit Search Search Filters Search This Site Search Cornell PORTENT A Center for Point of Care Technologies for Nutrition, Infection and Cancer Main Menu Toggle Search Form Home Resources & Approach PORTENT Approach PORTENT Clinical Network Capabilities Lab to Market Accelerator Educational Resources Webinars Leadership Team External Advisory Board Innovation Award Opportunity News & Events Funded Research Year 1 (2023-24) Projects Year 2 (2024-25) Projects Year 3 (2025-26) Projects Contact Us Home Gerard L. Coté Texas A&am … ient of several awards including the IEEE Sensors Council Technical Achievement Award, Sigma Xi Walston Chub Award for Innovation, the University of Connecticut School of Engineering Academy of Distinguished Engineers, the Distinguished Achievement Award for Graduate Mentoring, Distinguished Achievement Award for Research and the Distinguished Achievement Award for Teaching, all from the Texas A&M Association of Former Students. Cornell Research Resea … nell Environment, Health, and Safety Menu Home PORTENT Approach Team Innovation Award Opportunity Contact Us Portent [email protected] Room 139, Upson Hall Cornell University Ithaca, NY 14853 Part of Cornell Research & Innovation Follow us on: Cornell University ©2026 University Privacy If you have a disability and are having trouble accessing information on this website or need materials in an alternate format, contact us at [email protected] for assista
Innovator Shares Excitement About the Future of Innovation and Translational Research - Texas A&M Innovation Skip to content Submit a disclosure About Meet Our Team Employment Opportunities Photo Galleries Contact Us Inventors Invention Disclosure Inventor Process Funding Policies & Guidelines FAQs Industry Available Technologies New Ventures Events Innovation Forward Future 12 InnovationU Innovation Connect TNVC Innovation Awards Luncheon Sponsorship News Search Open mobile menu Close mobile menu Search Innovator Shares Excitement About the Future of Innovation and Translational Resea … was recently honored as the recipient of the 2024 Chancellor’s Innovation Award , underscoring his exceptional contributions to the field and his dedication to making a meaningful impact on society. Dr. Coté is a professor in the Department of Biomedical Engineering at Texas A&M University and an expert in biomedical diagnostic and monitoring research including creation of hand-held and wearable devices for chronic disease applications (e.g. diabetes, cardiac diseas … laboration with people from all backgrounds.” The Chancellor’s Innovation Award is a testament to Dr. Coté’s exemplary contributions and commitment to driving positive change in the world. As a trailblazer in health technologies and translational research, he inspires the next generation of inventors and researchers to strive for excellence in improving human health and well-being. Photo caption: Dr. Gerard Coté pictured in a laboratory. – Texas A&M Univ
Solutions - Bioxtek Skip to content Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Contact BioXtek BioPür Process Move to a regenerative, healing, and care model Unlike small molecules, interventions derived from human tissue up-regulate the body’s ability to self-heal. Allopathic treatments address a wide spectrum of medical and surgical pathologies, without side effects … ’s jelly. Aesthetic applications Facial aesthetics Hair aesthetics Topical Scar application Collagen Stimulation Hydration and Nourishment Competitive advantage These products support the delivery of the entire ‘symphonic orchestra’ needed for regenerative aesthetics. This product theoretically bolsters the building of robust collagen Regulatory pathway US FDA Registered Topical Cosmetic Full compliance with US FDA cosmetic regulations Commercialization Product currently sold
Contact Biotex - Bioxtek Skip to content Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Contact BioXtek Get in Touch Contact BioXtek Reach out to our clinical and order desk team for product information, pricing, ordering, and partnership inquiries. Get in Touch 316 Northeast 1st Street, Pompano Beach, FL 33060 +1 (954) 247-1977 [email protected] Name Phone Email Reason S
Home - Bioxtek Skip to content Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Contact BioXtek Leading the Perinatal Revolution The New Biologic Paradigm. We are transforming once-discarded birth byproducts into powerful, pharmaceutical-grade regenerative therapies. Eradicating disease at the cellular level, rather than endlessly managing symptoms. View Clinical Evidence Ex
Bioxtek — Whiteford Research Biobase Company DB ← Company DB Company information is AI generated, and may be inaccurate. BioXtek LLC Overview BioXtek LLC is a privately held Florida company developing and manufacturing regenerative biologic therapeutics, with a focus on human placental tissue-derived products. [1] The company is based in Pompano Beach, Florida, where AATB lists its accredited tissue-bank address at 316 Northeast 1st Street. [2] BioFuture's 2024 presenting-company profile describes BioXtek as a 2022 seed-stage company in Pompano Beach with Bruce Werber, DPM, MSc, as CEO and pre
BioTex Inc | www.inknowvation.com --> --> --> --> --> --> --> > https://gasparesganga.com/labs/jquery-loading-overlay/#examples --> > https://gasparesganga.com/labs/jquery-loading-overlay/#examples --> Skip to main content idi Toggle navigation 0 You have 0 notifications Site Visitor Site Visitor New To Inknowvation.com? Register now to get an access to proprietary SBIR-STTR databases! Registration is fast and free - start your access to business-actionable information today! Login Site Register Home My Work Area About My Work Area SBIR Community About SBIR Community SBIR Awardees Technology S … for medical, biomedical, and environmental applications Year Founded 1997 First Award 1997 Latest Award 2021 Program Status Active : At least one SBIR-STTR award (Phase I or Phase II) in last five years Inactive : Last award dollars more than FIVE years ago"> Program Status Active Popularity Index The Popularity Index is a rank (scale 1-100) assigned to each SBIR company, based on the number of hits to the company record. Currently Most Popular - click the name to see - … bs. Several of BioTex technologies have been out-licensed to achieve commercial application. The firm has aos successfuly spun off two companies: one being Visualase acquired by Medtronic in July 2014 for $104M; the other - Base Pair Biotechnologies - is an aptamer discovery and development company, spun out of Biotex, Inc. in 2012. Base Pair successfully raised $3.2M in financing in late 2017 Extent of SBIR involvement Phase I Awards 41 Phase II Awards 18 Conversion Rate Con … password. Please enter email address that is associated with your account. Back Submit ' type='hidden'> Still Need Help? If you need further assistance, send us an e-mail and we will assist you in resetting your account. Forgot password? Mail sent successfully. Enter username and password. Please enter email address that is associated with your account. Back Submit ' type='hidden'> Still Need Help? If you need further assistance, send us an e-mail and we will assist you in re
Ashok Gowda, PhD | Texas Life Science Forum Skip to main content BioHouston Rice Alliance Register Search Close Register Investors Sponsors Agenda Speakers Participating Companies Search Search Close Open Menu Close Register Investors Sponsors Agenda Speakers Participating Companies BioHouston Rice Alliance Register Enter a Search Term Search Ashok Gowda, PhD Founder and CEO, BioTex/Med Tex Ventures Dr. Gowda is a founder and CEO of the Houston-based medical technology developer and manufacturer, Biotex, Inc. To date, under his direction, the company has raised over $20M in non-dilutive fundin
Biotex Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contac … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Biotex - overview Location -, -, France Primary Industry Consumer Products About Biotex is a French company specializing in the design and production of plant-based memory foam pillows and mattresses, focusing on enhancing sleep quality through innovative and sustainable materials. Biotex designs and manuf … go Pro Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more. Sign in Request demo Our Company Who We Are Our Corporate Responsibility Partners
8-K 1 f8k010906_biotex.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------- FORM 8-K ---------------- CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 30, 2005 BIOTEX HOLDINGS, INC (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER) FLORIDA 000-50214 65-0968839 (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) (COMMISSION F
Team | Bayou troCarWash System © --> Team Home About Us Team News Contact Us × "> Home About Us Team Contact Us --> Home About Us Team News Contact Us Innovation starts here. Sharad H. Joshi CEO Sharad Joshi is a Global entrepreneurial medical devices CEO with a strong track record driving rapid global growth and laying the foundations for sustained success through strategic and product innovation, proven marketing and distribution channel building, and M&A/partnership leadership. He is a leader who fosters a mission-focused, fun, and collaborative environment, leading makeovers of s
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
--> Visualase | Biotex Inc. Company About Us Our Process Leadership Facility Careers Expertise Industrial Design Mechanical Electrical Software Services Research & Strategy Product Development Criterion Who We Are Consulting & Testing Services Contact Us Manufacturing Clinical What is a CRO Who We Are Consulting & Services Start-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog Company … rt-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog Contact Us Company About Us Our Process Leadership Facility Careers Expertise Industrial Design Mechanical Electrical Software Services Research & Strategy Product Development Criterion Who We Are Consulting & Testing S … rt-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog One of our greatest success stories, the Visualase technology disrupted the neurosurgery and urology markets with an innovative non-invasive thermal ablation system, recently acquired by Medtronic. Read more Problem Thermal abla
--> Who We Are | Biotex Inc. Company About Us Our Process Leadership Facility Careers Expertise Industrial Design Mechanical Electrical Software Services Research & Strategy Product Development Criterion Who We Are Consulting & Testing Services Contact Us Manufacturing Clinical What is a CRO Who We Are Consulting & Services Start-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog Compan … rt-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog Contact Us Company About Us Our Process Leadership Facility Careers Expertise Industrial Design Mechanical Electrical Software Services Research & Strategy Product Development Criterion Who We Are Consulting & Testing S … rt-up Services Monitoring Services Close-out Services Auditing Services Request Proposal Regulatory Commercialization Order Fulfillment Log in to ION Products Wirewatch Media Download IFU Case Studies Visualase Basepair Phasor Versaspine Redpoint Blog How Strong Is Your Team? Clinical research is a complex process. Each component is pivotal in achieving efficiency and accuracy in procedures, logistics, and results. You need a strong, complete, reliable clinical team that deli
Beyond Botox: Placenta Power, … ‑ Biohackers World Podcast ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 24 juin 13 min Beyond Botox: Placenta Power, Exosomes, and the Future of Regenerative Beauty Biohackers World Podcast Lire The idea that the body can help rebuild and repair itself still feels futuristic to many people, yet regenerative medicine has been quietly evolving for decades. Recorded live at Biohackers World Los Angeles, holistic nutritionist Shaina Simhaee speaks with Dr. Bruce Werber, CEO and Founder of BioXtek, surgeon, educator, and pioneer in regenerati
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization April 7, 2026 | 9 min read Twitter LinkedIn Facebook Email Print TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExo … etics Exosome Products Market Size, Share & Trends Analysis Distribution by Application, By Biological Source, By Product Format, End User, and Segment Forecasts, 2025-2034 ” Twitter LinkedIn Facebook Email Print Canada Europe Florida Manufacturing LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, 2026 · 4 min read · Heather McKenzie Layoff Tracker Biogen axes ‘s … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Beyond Botox: Placenta Power, ... - Biohackers World Podcast - Apple Podcasts بحث الرئيسية جديد قوائم الأفضل بحث ٢٤ يونيو ١٣ د Beyond Botox: Placenta Power, Exosomes, and the Future of Regenerative Beauty Biohackers World Podcast تشغيل The idea that the body can help rebuild and repair itself still feels futuristic to many people, yet regenerative medicine has been quietly evolving for decades. Recorded live at Biohackers World Los Angeles, holistic nutritionist Shaina Simhaee speaks with Dr. Bruce Werber, CEO and Founder of BioXtek, surgeon, educator, and pioneer in regenerative medicine with
How to Build Regenerative Medicine Efficiently? BioXtek Powers Operations with Odoo | Odoo Skip to Content Odoo Menu Sign in Try it free Apps Finance Accounting Invoicing Expenses Spreadsheet (BI) Documents Sign Sales CRM Sales POS Shop POS Restaurant Subscriptions Rental Websites Website Builder eCommerce Blog Forum Live Chat eLearning Supply Chain Inventory Manufacturing PLM Purchase Maintenance Quality Human Resources Employees Recruitment Time Off Appraisals Referrals Fleet Marketing Social Marketing Email Marketing SMS Marketing Events Marketing Automation Surveys Services Project Timeshe
Uncovering the Science of Regenerative Medicine Skip to content Search for: Home Episodes Books Sponsors About Contact Search for: Uncovering the Science of Regenerative Medicine with Dr. Bruce Werber Uncovering the Science of Regenerative Medicine with Dr. Bruce Werber Are you curious about the latest findings in regenerative medicine and how it’s changing the way we approach so many different conditions? On this week’s episode of the Pod of Inquiry, we’re joined by renowned physician, Dr. Bruce Werber the CEO of BioXtek to discuss the groundbreaking research in this field. … alez | S8 – E16 April 10, 2026 The Life Changing Arthritis Solution | Dr. Grant Pagdin | S6 – E22 July 4, 2025 The Hidden Truth About Varicose Veins | Dr. Amit Lakkaraju | S6 – E18 June 6, 2025 Cutting Edge Stem Cell Therapies In The Regenerative Revolution | Joshua Ketner | S6 – E13 May 2, 2025 Podcast (108) Podiatry (22) chronic pain (18) Neuropathy (17) Chronic Disease (16) Pain (16) Neurological (13) Diabetes (13) Biohacking (12) Nerve Pain (11) An
About Us - Bioxtek Skip to content Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Home The Science About Us Our Approach Solutions Products & Pipeline Clinical Evidence Compliance & Regulatory Contact Biotex Contact BioXtek Our Team The People Behind the Science Guided by seasoned clinicians, pharmaceutical executives, and distinguished scientists — united by a common mission to change how medicine heals. Our Team Leadership Team Board-Certified reconstructive surgeon for 35+ years. Leads clinica
Dr. Bruce Werber — Regenerative Surgeon & BioXtek CEO Events Biohack Store Community Blog About Us Events Biohack Store Community Blog About Us Dr. Bruce Werber DPM, MSc, FACFAS, CEO Founder of BioXtek Discover insights from the Speaker's groundbreaking journey and join us for an inspiring session Meet Speaker About SPEAKER About Dr. Bruce Werber Dr. Bruce Werber: A Visionary in Regenerative Medicine and Surgical Innovation Dr. Bruce Werber is a world-renowned surgeon, prolific inventor, and biotechnology pioneer with over 35 years of clinical experience, Throughout his distinguished caree
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ